Johns Hopkins Reveals How Blue Cones Transform Into Red, Green Vision Cells
Scientists at Johns Hopkins University have identified a precise, hormonally driven process that enables the human eye to develop the sharp central vision required for daytime perception. The study, published in the Proceedings of the National Academy of Sciences, reveals that the specialized arrangement of light-sensing cells in the center of the retina is established through the conversion of cell identities rather than the migration of cells, as previously theorized.
The Mechanics of Sharp Vision
The research focuses on the foveola, a tiny region at the center of the retina that accounts for approximately 50% of all human visual perception. Unlike the remainder of the retina, which contains a mix of blue, green, and red cone photoreceptors, the foveola is uniquely populated only by red and green cones.
For decades, the prevailing model in the scientific community suggested that blue cones formed in the central retina and subsequently migrated outward to make room for red and green cones. However, by utilizing lab-grown retinal organoids—small clusters of tissue derived from fetal cells—researchers discovered that the cells remain in place but undergo a fundamental shift in identity.
“The main model in the field from about 30 years ago was that somehow the few blue cones you get in that region just move out of the way, that these cells decide what they’re going to be, and they remain this type of cell forever,” said Robert J. Johnston Jr., an associate professor of biology at Johns Hopkins, who led the research. “We can’t really rule that out yet, but our data supports a different model. These cells actually convert over time, which is really surprising.”
A Coordinated Hormonal Sequence
The transformation process occurs during early fetal development through a two-step mechanism. According to the study, the retina follows a specific timeline:
* Weeks 10 through 12: A small number of blue cones appear in the developing foveola.
* Week 14: The remaining blue cones transform into red and green cones.
This shift is orchestrated by the interaction between a vitamin A-derived molecule and thyroid hormones. First, retinoic acid—a molecule derived from vitamin A—is broken down, which limits the formation of new blue cones. Following this, thyroid hormones trigger the remaining blue cones to convert into red and green cones.
“First, retinoic acid helps set the pattern. Then, thyroid hormone plays a role in converting the leftover cells,” Johnston explained. “That’s very important because if you have those blue cones in there, you don’t see as well.”
Challenges in Vision Research
The study addresses a long-standing difficulty in vision science: the lack of suitable animal models. Common research subjects, such as mice and fish, do not develop the same cone photoreceptor arrangement as humans, making the study of the foveola’s specific development historically challenging.
By using human retinal organoids, the Johns Hopkins team was able to observe these cellular events over several months. This method provides a new window into human eye development that was previously inaccessible, offering a potential pathway to address conditions that damage the center of the retina.
Implications for Future Therapies
The discovery of this conversion process is viewed as a significant step toward developing regenerative treatments for diseases like macular degeneration, which currently has no cure. Because the center of the retina is often the first area to fail in patients with such conditions, researchers hope that better understanding this developmental “blueprint” will allow them to replicate it in a laboratory setting.
“This is a key step toward understanding the inner workings of the center of the retina, a critical part of the eye and the first to fail in people with macular degeneration,” Johnston said.
The long-term goal for the research team is to create “made-to-order” populations of photoreceptors. By perfecting the use of organoids, scientists aim to eventually transplant healthy, lab-grown tissue into the human eye to restore vision lost to disease. While the team notes that these are long-term goals requiring extensive safety and efficacy studies before clinical application, they characterize the findings as a viable journey toward future cell replacement therapies.
Find more reporting in our Tech section.
